Tussibic - Butamirate Citrate | VetSafeCare.Com

Syrp.

Tussibic

Butamirate Citrate — UniMed UniHealth
50mg / tablet (sustained release) · 7.5mg / 5 ml

Alternatives

37

Routes

PO

Presentations

2

Generic profile Browse alternatives View combinations

Presentations

Tablet (Sustained Release) · 50mg / tablet (sustained release)

1 tablet (sustained release)

৳10

Syrup · 7.5mg / 5 ml

100 ml

৳80

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Use in adult: Butamirate Citrate 50 mg tablet: 2-3 tablets daily. Butamirate Citrate syrup: 15 ml 4 times daily. Use in children & adolescents:Butamirate Citrate 50 mg tablet: Adolescent over 12 years old: 1-2 tablets daily. Butamirate Citrate syrup: Children (3-6 yrs): 5 ml 3 times daily. Children (6-12 yrs): 10 ml 3 times daily. Adolescent: 15 ml 3 times daily. Butamirate Citrate pediatric drops: Children ( 2 months- 1 yrs): 0.50 ml 4 times daily. Children (1-3 yrs): 0.75 ml 4 times daily.

Clinical notes

Applications:

N/A

Indication Notes:
Butamirate Citrate is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butamirate Citrate is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any ... Read moreButamirate Citrate is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butamirate Citrate is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.
Avoid In:

N/A

Contraindication Notes:
Hypersensitivity to the active ingredient.
Butamirate Citrate acts directly on the brain's cough center to suppress cough. Butamirate Citrate is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. Butamirate Citrate is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with the sustained-release tablet. This is extremely protein-bound and plasma elimination half-life is about 13 hours. The active metabolites of Butamirate Citrate have also antitussive action.
Concomitant use with expectorants should be avoided.
Tolerance of Butamirate Citrate is good.Adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal.
Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.
Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butamirate Citrate administration during breast feeding should be carefully weighed against the risks.
Butamirate Citrate suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. If the cough persists for more than 7 days (more than 3 days in children younger than12 years of age) doctor must be consulted.